After completing its IPO and listing on the Hong Kong Stock Exchange, GenFleet Therapeutics (Shanghai) raised $233 million in gross proceeds and reached a market valuation of $934 million. Based on gross proceeds, this is the biggest IPO on the Hong Kong Stock Exchange under the Chapter 18A biotech listing regulation since 2022.